Agreement will provide BD with Cellomics's core high content screening patent portfolio that includes both broad claims to HCS technology and specific classes of HCS assays
Cellomics and BD Biosciences have entered into a non-exclusive, worldwide patent license agreement.
The agreement will provide BD with Cellomics's core high content screening patent portfolio that includes both broad claims to HCS technology and specific classes of HCS assays such as cytoplasm-nuclear translocation, characterisation of cellular toxicity, and receptor internalisation.
"We are very pleased to be working with BD to further expand the adoption and availability of high content screening technology.
"Through licensing of our HCS patent portfolio, we are seeking to enable customers to more effectively address complex biological questions," commented William Sharp, Cellomics's vice president of business development.
"With the recent acquisition of Atto Biosciences, and our licensing of this intellectual property from Cellomics, BD Biosciences extends our commitment to the area of high-content cellular analysis and strengthens our considerable capabilities in the area of live cell research that include high-resolution imaging, flow cytometry and a broad array of reagent systems," added Mark Lewis, vice president of BD Biosciences.
"Completion of this second significant licensing arrangement of our HCS patent portfolio with a global company like BD confirms the value of our extensive intellectual property in this critical area of drug discovery and reaffirms our intent to facilitate the expansion of the HCS market via an aggressive licensing and commercial strategy," stated Daniel Calvo, Cellomics's president and CEO.
